Stocktoria

RHYTHM PHARMACEUTICALS, INC. RYTM

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-10-05
Chart by TradingView
5/9
Piotroski F — financial health
-6.24
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$189.8M$130.1M$77.4M$23.6M$3.2M
Operating income-$192.0M-$265.5M-$184.4M-$179.2M-$170.1M
Net income-$196.5M-$260.6M-$184.7M-$181.1M-$69.6M
Operating cash flow-$115.7M-$113.9M-$136.2M-$173.4M-$146.0M
Free cash flow-$116.6M-$113.9M-$136.2M-$173.7M-$146.4M
Total assets$480.2M$392.3M$332.7M$382.5M$329.5M
Total liabilities$210.2M$227.7M$163.0M$118.2M$45.4M
Shareholders' equity$139.1M$21.7M$169.8M$264.3M$284.2M
Ratios
Operating margin-101.2%-204.0%-238.1%-757.9%-5391.9%
Net margin-103.6%-200.3%-238.5%-766.2%-2207.1%
FCF margin-61.5%-87.5%-175.9%-734.9%-4642.9%
Return on assets-40.9%-66.4%-55.5%-47.4%-21.1%
Return on equity-141.3%-1199.3%-108.8%-68.5%-24.5%
Debt / equity0.73×4.98×0.63×
Current ratio4.413.245.588.907.10
Revenue growth45.8%68.1%227.6%649.5%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.846,801$73.6M
RENAISSANCE TECHNOLOGIES LLC258,011$22.4M

Why these scores methodology →

Piotroski F-score: 5/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -6.24 (distress)

  • Working capital / assets 0.752
  • Retained earnings / assets -2.815
  • EBIT / assets -0.4
  • Equity / liabilities 0.662

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001649904 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.